TABLE 2.
FKBP12 and TOR mutations confer resistance to rapamycin and analogsa
| Straina | MICs and MFCs (μg/ml)b of:
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Rapamycin
|
Analog
|
|||||||||
| 2
|
18
|
19
|
23
|
|||||||
| MIC | MFC | MIC | MFC | MIC | MFC | MIC | MFC | MIC | MFC | |
| C. neoformans WT | 0.19 | 0.39 | 3.12 | 3.12 | >100 | >100 | >100 | >100 | 1.56 | 3.12 |
| C. neoformans frr1 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| C. neoformans TOR1-1 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| C. albicans WT | <0.09 | 0.39 | 6.25 | 12.5 | >100 | >100 | >100 | >100 | 0.78 | 0.78 |
| C. albicans rbp1/rbp1 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| C. albicans TOR1-1/TOR1 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
a
WT, wild type.
b
Drug dilutions were from 100 to 0.09 μg/ml.